Postprandial hyperlipidemia as a potential residual risk factor

Journal of Cardiology

Volumn 67, Issue 4, 2016, Pages 335-339

  Nakamura, Kazufumi ^a   Miyoshi, Toru ^a   Yunoki, Kei ^b   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Coronary heart disease; Postprandial hyperlipidemia; Residual risk factor; Triglyceride

Indexed keywords

EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN TRIGLYCERIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY RISK; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIET THERAPY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEUTROPHIL; OXIDATIVE STRESS; POSTPRANDIAL HYPERLIPIDEMIA; POSTPRANDIAL STATE; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 84958877090     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.12.001     Document Type: Review

References (48)

1. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
2. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., Kirby A., Sourjina T., Peto R., Collins R., Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014, 384:626-635.
4. Masuda D., Nakagawa-Toyama Y., Nakatani K., Inagaki M., Tsubakio-Yamamoto K., Sandoval J.C., Ohama T., Nishida M., Ishigami M., Yamashita S. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009, 39:689-698.
5. Yunoki K., Nakamura K., Miyoshi T., Enko K., Kohno K., Morita H., Kusano K.F., Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011, 217:486-491.
6. Miyoshi T., Noda Y., Ohno Y., Sugiyama H., Oe H., Nakamura K., Kohno K., Ito H. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial. Biomed Pharmacother 2014, 68:1071-1077.
7. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
8. Iso H., Naito Y., Sato S., Kitamura A., Okamura T., Sankai T., Shimamoto T., Iida M., Komachi Y. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001, 153:490-499.
9. Stensvold I., Tverdal A., Urdal P., Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993, 307:1318-1322.
10. Eberly L.E., Stamler J., Neaton J.D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003, 163:1077-1083.
11. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
12. Doran B., Guo Y., Xu J., Weintraub H., Mora S., Maron D.J., Bangalore S. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014, 130:546-553.
13. Tanaka A., Tomie N., Nakano T., Nakajima K., Yui K., Tamura M., Numano F. Measurement of postprandial remnant-like particles (RLPs) following a fat-loading test. Clin Chim Acta 1998, 275:43-52.
14. Tanaka A. Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 2004, 11:322-329.
15. Ai M., Tanaka A., Ogita K., Sekinc M., Numano F., Numano F., Reaven G.M. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. J Am Coll Cardiol 2001, 38:1628-1632.
16. Kim H.S., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 2001, 74:592-595.
17. Hussain M.M. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000, 148:1-15.
18. Tomono S., Kawazu S., Kato N., Ono T., Ishii C., Ito Y., Shimizu M., Shimoyama M., Nakano T., Nakajima K. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscler Thromb 1994, 1:98-102.
19. De Pascale C., Avella M., Perona J.S., Ruiz-Gutierrez V., Wheeler-Jones C.P., Botham K.M. Fatty acid composition of chylomicron remnant-like particles influences their uptake and induction of lipid accumulation in macrophages. FEBS J 2006, 273:5632-5640.
20. Bentley C., Hathaway N., Widdows J., Bejta F., De Pascale C., Avella M., Wheeler-Jones C.P., Botham K.M., Lawson C. Influence of chylomicron remnants on human monocyte activation in vitro. Nutr Metab Cardiovasc Dis 2011, 21:871-878.
21. Varbo A., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013, 128:1298-1309.
22. Varbo A., Benn M., Tybjaerg-Hansen A., Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436.
23. van Oostrom A.J., Sijmonsma T.P., Verseyden C., Jansen E.H., de Koning E.J., Rabelink T.J., Castro Cabezas M. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003, 44:576-583.
24. Norata G.D., Grigore L., Raselli S., Redaelli L., Hamsten A., Maggi F., Eriksson P., Catapano A.L. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193:321-327.
25. Ceriello A., Assaloni R., Da Ros R., Maier A., Piconi L., Quagliaro L., Esposito K., Giugliano D. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005, 111:2518-2524.
26. Zheng X.Y., Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007, 48:1673-1680.
27. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004, 109:1022-1028.
28. Ohara N., Takeichi S., Naito Y., Nakajima Y., Yukawa N., Nakano T., Nakajima K. Remnant-like particles from subjects who died of coronary artery disease suppress NO synthase activity and attenuate endothelium-dependent vasorelaxation. Clin Chim Acta 2003, 338:151-156.
29. Devaraj S., Venugopal S., Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 2006, 184:48-52.
30. Xu J.W., Morita I., Ikeda K., Miki T., Yamori Y. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 2007, 21:564-573.
31. Xia Z., Liu M., Wu Y., Sharma V., Luo T., Ouyang J., McNeill J.H. N-acetylcysteine attenuates TNF-alpha-induced human vascular endothelial cell apoptosis and restores eNOS expression. Eur J Pharmacol 2006, 550:134-142.
32. Marchesi S., Lupattelli G., Schillaci G., Pirro M., Siepi D., Roscini A.R., Pasqualini L., Mannarino E. Impaired flow-mediated vasoactivity during post-prandial phase in young healthy men. Atherosclerosis 2000, 153:397-402.
33. Bae J.H., Bassenge E., Kim K.B., Kim Y.N., Kim K.S., Lee H.J., Moon K.C., Lee M.S., Park K.Y., Schwemmer M. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001, 155:517-523.
34. Kugiyama K., Doi H., Motoyama T., Soejima H., Misumi K., Kawano H., Nakagawa O., Yoshimura M., Ogawa H., Matsumura T., Sugiyama S., Nakano T., Nakajima K., Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998, 97:2519-2526.
35. Teramoto T., Sasaki J., Ishibashi S., Birou S., Daida H., Dohi S., Egusa G., Hiro T., Hirobe K., Iida M., Kihara S., Kinoshita M., Maruyama C., Ohta T., Okamura T., et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version. J Atheroscler Thromb 2013, 20:517-523.
36. Bergeron N., Havel R.J. Assessment of postprandial lipemia: nutritional influences. Curr Opin Lipidol 1997, 8:43-52.
37. Harano Y., Miyawaki T., Nabiki J., Shibachi M., Adachi T., Ikeda M., Ueda F., Nakano T. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J 2006, 53:173-180.
38. O'Keefe J.H., Bell D.S. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100:899-904.
39. Noda Y., Miyoshi T., Oe H., Ohno Y., Nakamura K., Toh N., Kohno K., Morita H., Kusano K., Ito H. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013, 12:8.
40. Ohno Y., Miyoshi T., Noda Y., Oe H., Toh N., Nakamura K., Kohno K., Morita H., Ito H. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study. Cardiovasc Diabetol 2014, 13:71.
41. Tansey M.J., Tsalikian E., Beck R.W., Mauras N., Buckingham B.A., Weinzimer S.A., Janz K.F., Kollman C., Xing D., Ruedy K.J., Steffes M.W., Borland T.M., Singh R.J., Tamborlane W.V. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care 2006, 29:20-25.
42. Pirillo A., Norata G.D., Catapano A.L. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin 2014, 30:1489-1503.
43. Cannon C.P., Blazing M.A., Giugliano R.P., McCagg A., White J.A., Theroux P., Darius H., Lewis B.S., Ophuis T.O., Jukema J.W., De Ferrari G.M., Ruzyllo W., De Lucca P., Im K., Bohula E.A., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015, 372:2387-2397.
44. Tsujita K., Sugiyama S., Sumida H., Shimomura H., Yamashita T., Yamanaga K., Komura N., Sakamoto K., Oka H., Nakao K., Nakamura S., Ishihara M., Matsui K., Sakaino N., Nakamura N., et al. Impact of dual lipid-lowering strategy with Ezetimibe and Atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015, 66:495-507.
45. Yunoki K., Nakamura K., Miyoshi T., Enko K., Kubo M., Murakami M., Hata Y., Kohno K., Morita H., Kusano K.F., Ito H. Impact of hypertriglyceridemia on endothelial dysfunction during statin +/- ezetimibe therapy in patients with coronary heart disease. Am J Cardiol 2011, 108:333-339.
46. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Itakura H., Kita T., Kitabatake A., Nakaya N., Sakata T., Shimada K., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
47. Fruchart J.C. Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMalpha): the next generation of peroxisome proliferator-activated receptor alpha-agonists. Cardiovasc Diabetol 2013, 12:82.
48. Arai H., Ishibashi S., Yamashita S., Araki E., Yokote K., Suganami H., Kodama T. Efficacy and safety of K-877, a potent and selective PPAR-α modulator (SPPARMα), in combination with statins in Japanese patients with dyslipidemia. Circulation 2015, 132(Suppl. 3):A13374.